publication date: Mar. 31, 2016
20160331 - Mar. 31, 2016
March 2016PDF

 

 

Leukemia

Vyxeos Injection Improves Overall Survival In Phase III Acute Myeloid Leukemia Trial

A phase III trial of Vyxeos Liposome for Injection demonstrated statistically significant improvements in overall survival in patients with high-risk secondary acute myeloid leukemia.

The median overall survival for patients treated with Vyxeos (cytarabine: daunorubicin) in the study was 9.56 months compared to 5.95 months for patients receiving the standard of care regimen of cytarabine and daunorubicin known as 7+3.

The hazard ratio was 0.69 (p=0.005) which represents a 31 percent reduction in the risk of death versus 7+3, according to Celator Pharmaceuticals Inc., the drug’s sponsor, which plans to submit the data for presentation at the 2016 annual meeting of the American Society of Clinical Oncology.

 Non-Small Cell Lung Cancer

Atezolizumab Immunotherapy Boosts OS Compared to Docetaxel in Phase II Trial

Patients with advanced metastatic lung cancer treated with atezolizumab, a targeted immunotherapy drug, lived significantly longer and with fewer side effects than those who received docetaxel chemotherapy, according to a study published in The Lancet.

“The results of this study demonstrate that the use of atezolizumab, a monoclonal antibody, improves the survival rate of a majority of lung cancer patients who have progressive cancer when used after first-line chemotherapy,”

Also:

 Drugs and Targets

FDA Approves Imbruvica in First-Line CLL

FDA approved Imbruvica (ibrutinib) as a first-line treatment for patients with chronic lymphocytic leukemia.

The approval is based on data from the randomized, multi-center, open-label phase III RESONATE-2 trial, which evaluated the use of Imbruvica versus chlorambucil in 269 treatment-naïve patients with CLL or small lymphocytic lymphoma aged 65 years or older. The data were previously presented at the annual meeting of the American Society of Hematology in December 2015 and also published in The New England Journal of Medicine.

Also:

Ovarian Cancer

Study: Reolysin-Paclitaxel Combination Demonstrates Higher Response Than Paclitaxel Therapy Alone

 Glioblastoma

Tocagen Expands Phase II/III Trial, Begins Enrolling in Canada

 Cachexia

Two Phase III Anamorelin Trials Show Improved Lean Body Mass

 NCI CTEP-Approved Trials for the Month of March

Copyright (c) 2020 The Cancer Letter Inc.